# Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis

> **NCT06307223** · PHASE4 · COMPLETED · sponsor: **Second Affiliated Hospital of Xi'an Jiaotong University** · enrollment: 21 (actual)

## Conditions studied

- Malassezia Folliculitis

## Interventions

- **DRUG:** 30% supramolecular salicylic acid
- **DRUG:** supramolecular active zinc

## Key facts

- **NCT ID:** NCT06307223
- **Lead sponsor:** Second Affiliated Hospital of Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-07
- **Primary completion:** 2023-09-20
- **Final completion:** 2023-09-20
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06307223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06307223, "Efficacy and Safety of 30% Supramolecular Salicylic Acid Combined With Supramolecular Active Zinc in the Treatment of Malassezia Folliculitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06307223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*